Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pulmonx (LUNG) Net Margin (2019 - 2025)

Pulmonx (LUNG) has disclosed Net Margin for 7 consecutive years, with 64.78% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin rose 464.0% to 64.78% in Q3 2025 year-over-year; TTM through Sep 2025 was 61.87%, a 1020.0% increase, with the full-year FY2024 number at 67.3%, up 2129.0% from a year prior.
  • Net Margin was 64.78% for Q3 2025 at Pulmonx, down from 63.69% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 55.28% in Q4 2024 to a low of 146.76% in Q1 2022.
  • A 5-year average of 88.78% and a median of 84.57% in 2023 define the central range for Net Margin.
  • Biggest YoY gain for Net Margin was 21790bps in 2021; the steepest drop was -5259bps in 2021.
  • Pulmonx's Net Margin stood at 94.88% in 2021, then grew by 2bps to 92.6% in 2022, then increased by 22bps to 72.16% in 2023, then increased by 23bps to 55.28% in 2024, then fell by -17bps to 64.78% in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Net Margin are 64.78% (Q3 2025), 63.69% (Q2 2025), and 64.11% (Q1 2025).